Biohaven Therapeutics Ltd. has described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy, pain, dyskinesia, schizophrenia, anxiety disorders, stroke, Rett syndrome, substance abuse and dependence, among others.
Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd. have described 5-membered and 6-membered heterocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, viral infection, transplant rejection, cardiovascular and inflammatory disorders, and autoimmune, myeloproliferative and metabolic diseases.
Lhotse Bio Inc. has identified lysophospholipid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, chronic obstructive pulmonary disease, multiple sclerosis, inflammatory disorders, SARS-CoV-2 infection (COVID-19), transplant rejection and osteoporosis, among others.
Viva Star Biosciences (Suzhou) Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.
Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the treatment of cancer.
Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated several Masimo patents for physiological monitoring. However, the two companies are not finished with each other yet as the International Trade Commission has yet to rule on a similar case that could foreclose importation of Apple devices on grounds of patent infringement.
Medwatch Technologies Inc. reported a patent for the use of near infrared (NIR) spectroscopy, from collection of NIR LEDs surrounding a photo diode sensitive to wavelengths in the range 400 nm to 1650 nm, to noninvasively detect blood glucose concentrations, in a multi-sensing wearable device such as a watch or patch.
Researchers at Ontario Institute for Cancer Research and Sunnybrook Research Institute have described isoquinoline derivatives acting as apoptosis regulator BAX and/or BAK inhibitors reported to be useful for the treatment of neurodegenerative disorders.